LEXX

2.23

0.90% 0.02

Handel nachbörslich: 2.23

Lexaria Bioscience Corp (LEXX)

Überblick Nachrichten Preisverlauf Financials Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$2.21

Offen:

$2.22

24-Stunden-Volumen:

91,558

Relative Volume:

0.63

Marktkapitalisierung:

$38.92M

Einnahmen:

$411.00K

Nettoeinkommen (Verlust:

$-4.85M

KGV:

-1.9735

EPS:

-1.13

Netto-Cashflow:

$-4.88M

1W Leistung:

-0.45%

1M Leistung:

+1.36%

6M Leistung:

-22.57%

1J Leistung:

+71.54%

1-Tages-Spanne:

$2.15

$2.24

1-Wochen-Bereich:

$2.00

$2.31

52-Wochen-Spanne:

$1.20

$6.85

Lexaria Bioscience Corp Stock (LEXX) Company Profile

Firmenname

Lexaria Bioscience Corp

Sektor

Healthcare (1176)

Branche

Biotechnology (673)

Telefon

250-765-6424

Adresse

100 - 740 MCCURDY ROAD, KELOWNA

Mitarbeiter

Twitter

Nächster Verdiensttermin

2024-12-19

Neueste SEC-Einreichungen

LEXX's Discussions on Twitter

Vergleichen Sie LEXX mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
LEXX Lexaria Bioscience Corp	2.23	38.92M	411.00K	-4.85M	-4.88M	-0.44
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Lexaria Bioscience Corp Aktie (LEXX) Neueste Nachrichten

Dec 19, 2024

Lexaria's Registered GLP-1 Study #4 Begins Dosing - Yahoo Finance

Dec 19, 2024

Dec 18, 2024

Lexaria Bioscience finalizes clinical study agreement By Investing.com - Investing.com South Africa

Dec 18, 2024

Lexaria forms scientific advisory board to enhance drug delivery tech - Investing.com

Dec 18, 2024

Lexaria Bioscience Forms Elite Scientific Advisory Board with Harvard Medical School Expert - StockTitan

Dec 18, 2024

Dec 17, 2024

Lexaria Bioscience Taps Harvard Medical Expert to Accelerate GLP-1 & Hypertension Drug Development - StockTitan

Dec 17, 2024

Dec 10, 2024

Lexaria Bioscience engages CRO for human pilot study of DehydraTEHC-liraglutide - Yahoo Finance

Dec 10, 2024

Dec 09, 2024

Lexaria's Oral GLP-1 Drug Shows Promise: Plans First Human Trial After Beating Rybelsus in Animal Study - StockTitan

Dec 09, 2024

Liraglutide Processed with DehydraTECH to be Studied in Human GLP-1 Study #5 - Yahoo Finance

Dec 09, 2024

Dec 06, 2024

LEXX (Lexaria Bioscience) Enterprise Value : $38.78 Mil (As of Dec. 06, 2024) - GuruFocus.com

Dec 06, 2024

Dec 05, 2024

LEXX: Phase I Start Imminent - Yahoo Finance

Dec 05, 2024

Q1 EPS Forecast for Lexaria Bioscience Decreased by Analyst - Defense World

Dec 05, 2024

Dec 03, 2024

LEXX (Lexaria Bioscience) Market Cap : $47.13 Mil (As of Dec. 03, 2024) - GuruFocus.com

Dec 03, 2024

Insider Buying: Richard Christopher Acquires 50,000 Shares of Le - GuruFocus.com

Dec 03, 2024

Lexaria Bioscience CEO buys $118,391 in shares By Investing.com - Investing.com Nigeria

Dec 03, 2024

Lexaria Bioscience CEO buys $118,391 in shares - Investing.com

Dec 03, 2024

Lexaria Bioscience (NASDAQ:LEXX) Receives Buy Rating from HC Wainwright - Defense World

Dec 03, 2024

Dec 02, 2024

Lexaria Bioscience keeps stock target with Buy rating on financial results - Investing.com

Dec 02, 2024

Dec 01, 2024

LEXXW (Lexaria Bioscience) 3-Year Revenue Growth Rate : -39.20% (As of Aug. 2024) - GuruFocus.com

Dec 01, 2024

Nov 30, 2024

BTV Features these Stocks to Watch: Contango Ore, First Nordic Metals, Champion Iron, Prime Mining, Lexaria Bioscience, Osisko Development, West Red Lake Gold Mines, & Surge Battery Metals - Markets Insider

Nov 30, 2024

Lexaria's DehydraTECH Breakthrough: Fox Business to Spotlight Drug Delivery Innovation | LEXX Stock News - StockTitan

Nov 30, 2024

Nov 28, 2024

Lexaria Bioscience Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance

Nov 28, 2024

Nov 27, 2024

Lexaria: GLP-1 Drugs Expand Beyond Weight Loss Into Major Disease Treatments | LEXXW Stock News - StockTitan

Nov 26, 2024

Lexaria: GLP-1 Drugs Expand Beyond Weight Loss Into Major Disease Treatments - StockTitan

Nov 26, 2024

Nov 25, 2024

Lexaria Bioscience holds buy rating, steady stock target on positive study results - Investing.com Canada

Nov 25, 2024

Lexaria Completes Human Trial of Oral Tirzepatide Alternative to $15B Mounjaro Drug | LEXXW Stock News - StockTitan

Nov 25, 2024

Lexaria Completes Human Trial of Oral Tirzepatide Alternative to $15B Mounjaro Drug - StockTitan

Nov 25, 2024

Nov 20, 2024

Lexaria Bioscience’s DehydraTECH Outshines in Diabetes Study - TipRanks

Nov 20, 2024

ALL Study Groups Using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria's 12-Week GLP-1, Diabetes Animal Study - JCN Newswire

Nov 20, 2024

Lexaria's DehydraTECH Outperforms Rybelsus in Diabetes Study with 11.5% Better Weight Loss - StockTitan

Nov 20, 2024

Nov 15, 2024

LEXXWLexaria Bioscience Corp. Warrant Latest Stock News & Market Updates - StockTitan

Nov 15, 2024

Invenomic Capital Management LP Adjusts Stake in Lexaria Bioscie - GuruFocus.com

Nov 15, 2024

Nov 14, 2024

Lexaria commences unique drug distribution study - Investing.com

Nov 14, 2024

Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study - WICZ

Nov 14, 2024

Lexaria Signs Contract for New DehydraTECH GLP-1 Biodistribution Study - ACN Newswire

Nov 14, 2024

Lexaria Launches Groundbreaking Semaglutide Study vs. Rybelsus Formulation - StockTitan

Nov 14, 2024

Nov 13, 2024

LEXXLexaria Bioscience Corp. Latest Stock News & Market Updates - StockTitan

Nov 13, 2024

Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss - Yahoo Finance

Nov 13, 2024

Nov 12, 2024